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Rapamycin promotes arterial thrombosis in vivo: implications
for everolimus and zotarolimus eluting stents
Abstract
AIMS: Drug-eluting stents (DES) may be associated with an increased risk for stent thrombosis when
compared with bare-metal stents. In endothelial cells, rapamycin induces tissue factor (TF) by inhibiting
the mammalian target of rapamycin (mTOR). However, the effect of mTOR inhibition on TF activity
and thrombus formation in vivo has not yet been studied. Moreover, it is unclear whether
second-generation DES substances everolimus and zotarolimus have an effect on endothelial TF
expression. METHODS AND RESULTS: In a mouse carotid artery photochemical injury model,
rapamycin (182 +/- 27.5 microg/L) decreased time to thrombotic occlusion by 40%, increased TF
activity, and abrogated p70S6K phosphorylation when compared with controls. In vitro, rapamycin,
everolimus, and zotarolimus (each 10(-7) mol/l) enhanced TNF-alpha-induced TF expression by 2.2-,
1.7-, and 2.4-fold, respectively, which was paralleled by an increase in TF surface activity. Similar to
rapamycin, everolimus and zotarolimus abrogated TNF-alpha-induced p70S6K phosphorylation under
these conditions. CONCLUSION: Rapamycin increases TF activity and promotes arterial thrombosis in
vivo at concentrations relevant in patients undergoing DES implantation; this effect may increase the
thrombogenicity of DES. Since everolimus and zotarolimus augment endothelial TF expression and
activity in vitro in a similar manner as rapamycin, these findings may also be relevant for second
generation DES.
European Heart Journal, 2009 
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ABSTRACT 
 
Background – Drug-eluting stents (DES) may be associated with an increased risk 
for stent thrombosis as compared to bare-metal stents (BMS). In endothelial cells, 
rapamycin induces tissue factor (TF) by inhibiting the mammalian target of rapamycin 
(mTOR). However, the effect of mTOR inhibition on TF activity and thrombus 
formation in vivo has not yet been studied. Moreover, it is unclear whether second-
generation DES substances everolimus and zotarolimus have an effect on 
endothelial TF expression.  
Methods and Results – In a mouse carotid artery photochemical injury model, 
rapamycin decreased time to thrombotic occlusion by 40%, increased TF activity, 
and abrogated p70S6K phosphorylation as compared to controls. In vitro, rapamycin, 
everolimus, and zotarolimus (each 10-7 mol/l) enhanced TNF-α induced TF 
expression by  2.2-, 1.7-, and 2.4-fold, respectively, which was paralleled by an 
increase in TF surface activity. Similar to rapamycin, everolimus and zotarolimus 
abrogated TNF-α-induced p70S6K phosphorylation under these conditions.  
Conclusions – Rapamycin increases TF activity and promotes arterial thrombosis in 
vivo at concentrations relevant in patients undergoing DES implantation; this effect 
may increase the thrombogenicity of DES. Since everolimus and zotarolimus 
augment endothelial TF expression and activity in vitro in a similar manner as 
rapamycin, these findings may also be relevant for second generation DES. 
 
Key words: drug-eluting stents – thrombosis – tissue factor 
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INTRODUCTION 
 
Percutaneous coronary intervention (PCI) and stenting of the culprit lesion is 
the preferred treatment in acute myocardial infarction.(1-3) Drug-eluting stents (DES) 
are associated with reduced restenosis rates as compared to bare-metal stents 
(BMS).(4-6) However, stent thrombosis rates are not reduced in DES and may even 
be higher as compared to BMS, particularly in acute coronary syndromes (ACS).(6-
13) Since it is associated with a high mortality, stent thrombosis remains one of the 
most dreaded complications of interventional cardiology. Indeed, stent thrombosis is 
believed to be one possible reason for the lack of a true mortality benefit with DES as 
compared to BMS.(14, 15) Second-generation DES such as everolimus- and 
zotarolimus-eluting stents are proposed to display a better safety profile compared to 
first-generation DES, but long term, large scale clinical data supporting this 
hypothesis are lacking.  
Initiation of coagulation is a pivotal event in the pathogenesis of thrombosis 
and acute myocardial infarction. Tissue factor (TF) is a key trigger of the coagulation 
cascade; it activates factor X by binding activated factor VII (FVIIa), which ultimately 
leads to thrombin formation.(16) Rapamycin, a macrocyclic lacton used on first-
generation DES, induces TF in human endothelial cells by inhibiting the activity of the 
mammalian target of rapamycin (mTOR).(17) However, the effect of mTOR inhibition 
on TF activity and thrombus formation in vivo has not yet been studied. Moreover, 
whether and to what degree the rapamycin analogues everolimus and zotarolimus 
exert similar effects on endothelial TF expression is unknown. Thus, the present 
study was designed to investigate the role of mTOR inhibition on TF induction and 
arterial thrombosis in vivo and to examine the effect of everolimus and zotarolimus 
on TF expression human endothelial cells. 
 
 
MATERIALS AND METHODS 
 
Carotid Artery Thrombosis Model 
C57BL/6 mice (6 to 8 weeks old; Charles River Laboratories, Sulzfeld, 
Germany) weighing an average of 23±2 g were treated with rapamycin (2 mg/kg body 
weight) or with vehicle by intraperitoneal injection. After 1 hour, mice were 
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anesthetized with intraperitoneal injection of 2 mg of sodium pentobarbital (Butler, 
Columbus, Ohio) as described previously.(18, 19) Rose Bengal (Fisher Scientific, 
Fair Lawn, NJ) was diluted to 10 mg/mL in PBS and then injected into the tail vein in 
a volume of 0.12 mL at a final concentration of 50 mg/kg with a 27-gauge Precision 
Glide needle with a 1-mL latex free syringe (Becton Dickinson, Franklin Lakes, NJ). 
Once anesthetized, mice were secured in a supine position, placed under a 
dissecting microscope (Olympus C-4040 Zoom; spatial resolution 4.1 megapixels, 
Olympus Schweiz, AG, Switzerland), and the right common carotid artery was 
exposed after a midline cervical incision. A Doppler flow probe (model 0.5 VB, 
Transonic Systems, Ithaca, NY) was gently applied to the right common carotid 
artery and connected to a flowmeter (Transonic, model T106). Six minutes after rose 
bengal injection, a 1.5-mW green light laser (540 nm; Melles Griot, Carlsbad, CA) 
was applied to the desired site of injury at a distance of 6 cm for 60 minutes or until 
thrombosis occurred. From the onset of injury, blood flow in the vessel was 
monitored for 120 minutes, at which time the experiment was terminated. Occlusion 
was defined as a flow of ≤ 0.1 mL/min for at least 1 minute.(19, 20) At the time of 
cessation of blood flow, the appearance of an occlusive thrombus was clearly visible 
through the microscope in the lumen of the artery. 
 
Tissue factor activity in vitro and in vivo  
TF cell surface and total tissue activity were analyzed in HAEC and mouse 
carotid artery homogenates, respectively, with a colorimetric assay (American 
Diagnostica) as described.(19, 21)  
HAEC were grown in 12-well plates; after stimulation, cells were washed twice 
with phosphate-buffered saline (PBS) followed by incubation with human factor VIIa 
(FVIIa) and factor X (FX) at 37°C, resulting in the formation of TF/FVIIa complex at 
the cell surface. Right carotid arteries were homogenized in 50μL of lysis buffer (50 
mmol Tris-HCl, 100 mmol NaCl, 0.1% Triton X-100, pH 7.4) 1 hour after 
intraperitoneal application of rapamycin (2 mg/kg body weight) or vehicle and left to 
stand on ice for 30 minutes. In either case, the TF/FVIIa complex converted human 
FX to factor Xa, which was measured by its ability to cleave a chromogenic 
substrate. A standard curve with lipidated human TF was performed to ensure that 
measurements were taken in the linear range of detection (data not shown). 
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Cell culture 
HAEC were cultured as described.(21) Cells were grown to confluence in 3.5 
cm dishes and rendered quiescent for 24 hours before stimulation with TNF-α 
(Sigma, Munich, Germany). Rapamycin, everolimus (both from Sigma), and 
zotarolimus (a kind gift from Abbott Vascular, Santa Clara, CA) were added 60 
minutes prior to stimulation.  
 
Western blot analysis  
Protein expression was determined by Western blot analysis.(17) Cells were 
lysed in 50 mM TRIS buffer and 30-40 µg samples were loaded and separated by 
10% SDS-PAGE. Proteins were transferred to a PVDF membrane (Millipore, 
Billerica, MA) by semidry transfer. The antibody to human TF (American Diagnostica, 
Pfungstadt, Germany) was used at 1:1000 dilution; antibodies against the 
phosphorylated Thr-389-residue of p70S6 kinase (S6K) and against total S6K (both 
from Cell Signaling) were used at 1:1’000 and 1:2’000 dilution, respectively. Blots 
were normalized to GAPDH expression (1:20’000 dilution, Sigma).  
 1 hour after intraperitoneal application of rapamycin (2 mg/kg body weight) or 
vehicle (2.5% DMSO in phosphate buffered saline (PBS)), aortas of mice  were 
homogenized in 50 μL of lysis buffer (50 mmol Tris-HCl, 100 mmol NaCl, 0.1% Triton 
X-100, pH 7.4) and left to stand on ice for 30 minutes. 100 μg samples were loaded 
and separated by 10% SDS-PAGE; proteins were transferred to a PVDF membrane 
and probed with an antibody to phosphorylated p70S6K (1:1000 dilution) or total 
p70S6K (1:2000 dilution). 
 
Statistics 
Data are presented as mean ± standard error of the mean (SEM). Unpaired 
Student t test was applied to compare 2 groups; ANOVA with Bonferroni’s correction 
was used for ≥ 3 groups. A p value <0.05 was considered significant.  
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RESULTS 
 
Rapamycin inhibits mTOR, increases TF activity, and promotes arterial 
thrombosis in vivo.  
Photochemically induced arterial injury, an established model of arterial 
thrombosis,(18-20, 22) was applied to study arterial thrombus formation. Vehicle-
treated mice developed thrombotic occlusion within 36.0 ± 6.4 minutes (Fig. 1A left 
column). Treatment with rapamycin (2 mg/kg body weight) shortened time to 
thrombotic vessel occlusion by 40% to 21.4 ± 2.4 minutes (p<0.05; Fig 1A, right 
column). Plasma levels of rapamycin 1 hour after intraperitoneal injection were 182 
μg/l (± 13,7 μg/l; n=4).  
Photochemical arterial injury is dependent on TF.(18) Treatment of mice with 
rapamycin (2 mg/kg body weight) increased TF activity in carotid arteries by 45% as 
compared to TF activity in carotid arteries of vehicle-treated mice (Fig. 1B; p=0.01).  
 Phosphorylation of p70S6K, a downstream target of mTOR, is frequently used 
to assess mTOR inhibition by rapamycin,(17, 23, 24)  and abrogation of p70S6K 
phosphorylation leads to an increase in TF expression and activity.(17) While a 
prominent phosphorylation of p70S6K was observed in aortas of mice treated with 
vehicle, it was abrogated in rapamycin-treated animals (Fig. 1C; p<0.01).  
There was no change in activated partial thromboplastin time (aPTT; 25.5 ± 
0.5 sec. vs. 24.4 ± 0.8 sec., p=n.s.) or prothrombin time (PT; 11.1 ± 0.1 sec. vs. 11.4 
± 0.2 sec., p=n.s.) in rapamycin-treated versus control mice, respectively (Table 1). 
 
Rapamycin enhances TF expression in human endothelial cells 
Stimulation of HAEC with TNF-α (5 ng/ml) induced TF protein expression (Fig. 
2). Rapamycin (10-9-10-7 mol/l) resulted in a concentration-dependent enhancement 
of TF expression with a maximal increase of 2.2-fold as compared to stimulation with 
TNF-α alone and 75-fold as compared to the unstimulated control (Fig 2A; p<0.02 for 
rapamycin 10-7 mol/l vs. TNF-α alone). Rapamycin (10-7 mol/l) abrogated p70S6K 
phosphorylation (Fig. 2B). 
 
Everolimus and zotarolimus enhance TF expression in human endothelial cells 
Like rapamycin, everolimus (10-9-10-7 mol/l) and zotarolimus (10-9-10-7 mol/l)  
enhanced TNF-α induced TF expression in a concentration-dependent manner (n=3; 
  6 / 22 
Camici et al., 2009  Rapamycin Promotes Arterial Thrombosis 
p<0.05, data not shown). When compared side-by-side (each substance 10-7 mol/l), 
the maximal increase in TF induction was 2.2-, 1.7-, and 2.4-fold for rapamycin, 
everolimus, and zotarolimus, respectively, as compared to TNF-α (Fig. 3A; p<0.005 
for everolimus vs. TNF-α alone and p<0.001 for zotarolimus vs. TNF-α alone). TF 
induction by zotarolimus+TNF-α was 1.4-fold higher as compared to 
everolimus+TNF-α (p<0.05).  
Rapamycin increased TNF-α induced TF surface activity by 1.5-fold; similarly, 
everolimus and zotarolimus augmented TNF-α induced TF surface activity by 1.4-fold 
and 1.5-fold, respectively (Fig. 3B; p<0.01 for everolimus or zotarolimus vs. TNF-α 
alone). Similar to rapamycin (Fig 2B), everolimus (Fig. 3C, upper panel) and 
zotarolimus (Fig. 3C, lower panel) abrogated TNF-α induced p70S6K 
phosphorylation.  
 
  
DISCUSSION 
 
Rapamycin was previously shown to induce TF in vitro; yet, the physiological 
significance of this effect has not been assessed.(17) The findings of the present 
study suggest that this effect is also relevant in vivo, since inhibition of mTOR by 
rapamycin increases TF activity and promotes arterial thrombosis in the mouse 
carotid artery exposed to laser injury. Moreover, everolimus and zotarolimus inhibit 
mTOR and enhance TF expression and activity in human endothelial cells similar to 
rapamycin, indicating that these findings may be relevant both for first- and second 
generation DES. 
The inhibitory role of the mammalian target of rapamycin (mTOR) on TF 
expression is established, as its inhibition enhances TF expression in response to a 
variety of mediators in vitro.(17, 19, 25) Binding of rapamycin to its intracellular 
receptor, FKBP-12, leads to the formation of the rapamycin-FKBP-12 complex, which 
in turn inhibits mTOR activity. In contrast, TF-FVIIa-FXa complex itself may induce 
phosphorylation of mTOR (and p70S6K), consistent with a negative feedback 
mechanism.(26) Phosphorylation of the downstream target of mTOR, p70S6K, is 
widely used as a readout for the inhibitory effect of rapamycin,(23, 24) since mTOR-
dependent phosphorylation of the Thr-389 residue of p70S6K is necessary for its 
activity.(23) Rapamycin is known to abrogate p70S6K phosphorylation,(17) and the 
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present study demonstrates that the rapamycin analogues everolimus and 
zotarolimus equally do so, supporting the interpretation that inhibition of mTOR 
promotes TF induction.(17)  
Biologically active TF (which is located at the cell surface) is induced by all 
three drugs to a very similar degree in vitro. In the case of rapamycin and 
zotarolimus, the increase in TF surface activity was not as pronounced as that in 
protein expression. Similar discrepancies between the degree of protein expression 
and surface activity have also been observed in previous studies,(17, 21) and may 
be accounted for by the expression of encrypted TF and / or the distribution of TF in 
several cellular compartments.(27)  
The dose of rapamycin used in our in vivo experiments (2 mg/kg body weight) 
corresponds to that employed in previous murine studies.(28) Rapamycin plasma 
levels 1 hour after intraperitoneal injection (i.e., at the time of thrombosis) were 182 
μg/l, corresponding to 2x10-7 mol/l; hence, plasma levels in vivo were similar to the 
concentrations employed in vitro. Maximal systemic concentrations of rapamycin 
after deployment of 2 sirolimus-eluting stents are reported to be ~1 ng/mL (~1.15 x 
10-9 mol/l).(29) Although difficult to assess, local concentrations after stent 
deployment at the cellular level are likely to be significantly higher than systemic 
levels due to the lipophilic properties of these agents, which tend to accumulate in 
the vessel wall.(8, 30-32) Hence, the concentrations used in our study both in vivo 
and in vitro are likely to be relevant for patients treated with DES. 
When employed to prevent organ rejection after transplantation, rapamycin 
target levels are around 10 ng/ml (corresponding to 10-8 mol/l). Interestingly, cases of 
thrombotic microangiopathy have been described during treatment with rapamycin 
(with or without a calcineurin inhibitor) in transplant recipients with chronic graft-
versus-host-disease as well as after renal transplantation.(33, 34) Thrombotic 
complications were also observed in patients treated with rapamycin after liver 
transplantation.(34) The concentrations used in our in vivo experiments are around 
10-fold higher than target levels after transplantation, which would explain why these 
complications do not occur more frequently. However, it is conceivable that under 
certain circumstances rapamycin may have a prothrombotic effect in patients 
receiving the drug to prevent organ rejection.  
In spite of the obvious success of DES, several shortcomings have been noted 
since their introduction including the risk of stent thrombosis.(12) While some studies 
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found similar thrombosis rates in first-generation DES and BMS,(35, 36) others have 
described an increased risk in DES.(7, 10-12) Even though long-term large-scale 
studies are currently underway to assess this issue, the fear of stent thrombosis 
remains high owing to the oftentimes severe clinical consequences. The occurrence 
of stent thrombosis has been reported both with everolimus- and zotarolimus-eluting 
stent systems;(37, 38) as the number of patients studied and the follow-up duration 
are still limited, it is so far impossible to infer, whether the risk of stent thrombosis is 
increased in such second-generation DES as compared to first-generation DES or 
BMS.  
Several mechanisms of stent thrombosis are currently discussed, of which 
delayed endothelial healing is presently thought to be most relevant.(12) Re-
endothelialization is initiated soon after vascular injury, and has been observed to 
begin as early as 2 days after balloon dilatation in animal models.(39-41) In humans, 
partial re-endothelialization is observed at 3 weeks after stent deployment.(41-43) 
Impaired re-endothelialization may be a particularly important cause of stent 
thrombosis in conditions with local inflammation, such as in acute coronary 
syndromes (ACS). In a recent autopsy study of patients treated with DES for acute 
myocardial infarction, vessel healing at the culprit site was indeed substantially 
delayed as compared to those treated for stable angina, suggesting an increased 
thrombotic risk in the former group of patients.(44) Our data demonstrating enhanced 
TF activity as well as increased arterial thrombogenicity in the setting of mTOR 
inhibition by rapamycin support the interpretation that TF may also play an important 
role in the pathogenesis of stent thrombosis, which may be even more pronounced in 
the inflammatory microenvironment of acute myocardial infarction. Rapamycin-
coated stents elute about 80% of the drug by 30 days.(4, 5) However, rapamycin 
easily penetrates cell walls due to its lipophilic properties resulting in long-term 
retention of the drug in arterial tissue.(30-32) Hence, the time course of re-
endothelialization as well as the kinetics of rapamycin release imply that rapamycin-
enhanced endothelial TF expression may potentially play a role in the pathogenesis 
of acute and subacute stent thrombosis, while it may be less relevant for late stent 
thrombosis. Importantly, prothrombin time (PT), which by virtue of its measurement is 
dependent on factor VII and exogenous TF, remained unchanged after treatment of 
mice with rapamycin, indicating that an increase in vessel-wall derived TF is 
responsible for the observed enhanced thrombogenicity. To expand on these 
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observations, further studies are needed to investigate the extent and the pattern of 
TF expression in the arterial wall after deployment of both first- and second-
generation DES.  
Furthermore, substances eluted from DES may have an effect not only on the 
stented arterial segment, but also on the endothelium distal to the stent. Indeed, 
impaired endothelial function was demonstrated by quantitative coronary 
angiography in coronary arteries distal to rapamycin-eluting stent implantation.(45, 
46) Thus, rapamycin, everolimus, or zotarolimus may not only increase TF in the 
stented segment, but also in endothelial cells in the immediate vicinity as well as in 
the more distal circulation. Such an effect may potentially contribute to no-reflow 
phenomena after stent deployment. 
While the current study compares the in vitro TF induction of rapamycin, 
everolimus, and zotarolimus it does not compare TF activity and thrombus formation 
in vivo amongst the three drugs; in order to do so correctly and adequately, 
measurement of in vivo plasma levels over time of all three drugs as well as 
appropriate adjustment of the applied doses of the drugs would be required, which 
seems beyond the scope of the current study. Instead, we demonstrate for the first 
time in vivo (as a proof-of-principle) that rapamycin inhibits arterial mTOR activity, 
increases arterial TF activity and promotes thrombus formation without affecting 
systemic coagulation parameters. Given the similar effect of everolimus and 
zotarolimus on TF expression as well as on p70S6K phosphorylation in vitro, an 
increase in TF activity and promotion of thrombus formation in vivo is nevertheless 
likely to occur with these two drugs as well. 
In summary, this study reveals that inhibition of mTOR increases TF activity 
and promotes arterial thrombosis in vivo, which may favor the development of 
thrombosis in DES. As everolimus and zotarolimus equally increase TF expression 
and activity in vitro, these findings may be relevant for both first- and second 
generation DES. 
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FIGURE LEGENDS 
 
Fig. 1: Rapamycin inhibits mTOR, increases TF activity, and promotes arterial 
thrombosis in vivo. 
A) Treatment with rapamycin shortens time to thrombotic carotid artery occlusion. 
*p<0.05 versus vehicle-treated mice; n≥6 for each group.  
B) Rapamycin increases TF activity in mouse carotid artery. Values are given as 
absorbance at 405 nm. *p=0.01 versus vehicle-treated mice, n=5 for each group. 
C) Treatment with rapamycin inhibits mTOR activity in vivo as evidenced by reduced 
p70S6K phosphorylation. *p<0.01 versus vehicle-treated mice, n=5 for each group. 
 
Fig. 2: Rapamycin inhibits mTOR and enhances endothelial tissue factor 
expression in human endothelial cells 
A) Rapamycin enhances TNF-α-induced TF expression in a concentration-dependent 
manner. *p<0.02 versus TNF-α alone.  
B) Rapamycin completely abrogates p70S6K phosphorylation.(17) Total levels of 
p70S6K remain unchanged. Blots are representative of two independent 
experiments.  
 
Fig. 3: Everolimus and zotarolimus induce tissue factor expression and surface 
activity 
A) Comparison of maximal increase in rapamycin-, everolimus-, and zotarolimus-
enhanced TF expression. * p<0.02 and ** p<0.005 versus TNF-α alone; *** p<0.001 
versus TNF-α alone and *** p<0.05 versus everolimus (using ANOVA with 
Bonferroni’s correction). Blots are representative of at least three independent 
experiments, and values are given as percentage of stimulation with TNF-α alone. 
B) Rapamycin, everolimus, and zotarolimus enhance TNF-α induced TF surface 
activity. Values are given as percentage of stimulation with TNF-α alone. * p<0.01 
versus TNF-α alone; n=3.  
Everolimus (C, upper panel) and zotarolimus (C, lower panel) abrogate p70S6K 
phosphorylation. Total levels of p70S6K remain unchanged. Blots are representative 
of four independent experiments. 
TF = Tissue factor, Ra = Rapamycin, Ev = Everolimus, Zo = Zotarolimus. 
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Table 1: Rapamycin has no effect on activated partial thromboplastin time 
(aPTT) and prothrombin time (PT) 
aPTT and PT were unchanged 1 hour after treatment of mice with rapamycin (2 
mg/kg body weight) as compared to vehicle treated mice (p=n.s.). 
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Figure 1: 
 
0
10
20
30
40
50
Control
Ti
m
e 
to
 o
cc
lu
si
on
 
(m
in
ut
es
)
*
Rapamycin
A
B
C
0.00
0.02
0.04
0.06
0.08
0.10
Control
Ti
ss
ue
 F
ac
to
r 
ac
tiv
ity
 
(O
D 
Δ4
50
nm
)
Rapamycin
*
0.00
0.05
0.10
0.15
0.20
p7
0S
6K
 p
ho
sp
ho
ry
la
tio
n
(O
D,
 a
rb
itr
ar
y 
un
its
)
*
Pho p70
Tot p70
Control Rapamycin
 
 
 
 
 
 
  19 / 22 
Camici et al., 2009  Rapamycin Promotes Arterial Thrombosis 
Figure 2: 
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Figure 3: 
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Table 1: 
 
Control Rapamycin p
aPTT (sec) 24.38 +/- 0.81 25.46 +/ -0.54 0.30
PT (sec) 11.42 +/- 0.19 11.12 +/- 0.09 0.20
 
 
 
 
 
 
 
 
 
